Table 3.
Associations of pre-surgery metabolite concentrations with risk of early recurrence (recurrence occurred within 24 months after diagnosis) in prospectively followed colorectal cancer patients. Analysis is adjusted for age, sex, tumor stage, tumor site, BMI, adjuvant treatment, and study cohort.
| Metabolite | N Patients 1 (N Events 2) | HR (95% Confidence Interval) | p | pFDR |
|---|---|---|---|---|
| Lysophosphatidylcholine (acyl) C20:4 | 438 (44) | 0.67 (0.47, 0.96) | 0.03 | 0.76 |
| Hydroxysphingomyeline C16:1 | 438 (44) | 0.69 (0.48, 0.99) | <0.01 | 0.76 |
| Sphingomyeline C18:1 | 438 (44) | 0.56 (0.36, 0.85) | <0.01 | 0.76 |
| Sphingomyeline C20:2 | 438 (44) | 0.67 (0.46, 0.97) | 0.03 | 0.76 |
1 Patients who were not diagnosed with a recurrence during the study follow-up. 2 Patients who were diagnosed with a recurrence during study follow-up.